According to the latest market intelligence report published by Future Market Insights (FMI), the global pharmacovigilance market is estimated at USD 9.8 billion in 2026, up from USD 9.0 billion in 2025, and is projected to reach USD 22.8 billion by 2036. The market is expected to expand at a compound annual growth rate (CAGR) of 8.8% between 2026 and 2036, supported by growing pharmaceutical safety requirements, clinical trial activity, post-marketing surveillance, and demand for reliable adverse-event reporting and assessment.

Pharmacovigilance encompasses the detection, assessment, understanding, and prevention of adverse effects and other medicine-related safety problems. As pharmaceutical and biotechnology companies develop increasingly complex drug portfolios, effective safety monitoring remains essential throughout clinical development and after products reach the market.

👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1107

FMI's report identifies clinical trial pharmacovigilance as the leading type segment, with a 28.7% share in 2026. The clinical phase represents 35.0% of the phases segment, while small-molecule drugs account for 29.5% of the drug-class segment.

Market Size and Growth Forecasts

·         2025 Baseline Market Value: USD 9.0 billion

·         2026 Estimated Market Size: USD 9.8 billion

·         2036 Projected Market Value: USD 22.8 billion

·         Forecast CAGR: 8.8% (2026–2036)

·         Incremental Growth Opportunity: USD 13.8 billion

·         Leading Pharmacovigilance Type: Clinical trial pharmacovigilance, with a 28.7% share in 2026

·         Leading Phase Segment: Clinical phase, with a 35.0% share

·         Leading Drug-Class Segment: Small-molecule drugs, with a 29.5% share

The projected expansion reflects the continued need to collect and evaluate safety information across clinical trials and routine medical use. Pharmaceutical companies must maintain processes for reviewing suspected adverse reactions, documenting safety findings, and meeting applicable reporting obligations.

Key Market Segments

By Type of Pharmacovigilance

Clinical trial pharmacovigilance accounts for 28.7% of market revenue in 2026. This segment supports the collection, evaluation, and reporting of safety information during clinical development. Increasingly complex clinical programs and the need for consistent safety processes across study sites reinforce demand for specialized expertise and supporting technology.

Post-marketing pharmacovigilance is also important because safety monitoring continues after a medicine receives authorization. Real-world reports can reveal potential safety signals that may not have been apparent during clinical trials, supporting ongoing assessment of a medicine's benefit-risk profile.

Other categories include comparative pharmacovigilance, vaccine pharmacovigilance, and monitoring associated with herbal and traditional medicines.

By Phase and Drug Class

Clinical-phase activities represent 35.0% of the phases segment. These activities support safety monitoring during drug development, when adverse-event information must be evaluated as clinical evidence accumulates.

Small-molecule drugs account for 29.5% of drug-class revenue in 2026. The market also covers large-molecule medicines and herbal and natural products, reflecting the range of therapeutic products requiring structured safety oversight.

By Delivery Mode and End User

Pharmacovigilance may be managed through in-house teams or outsourced service providers. Pharmaceutical companies, biotechnology businesses, contract research organizations (CROs), business process outsourcing firms, regulatory authorities, and healthcare providers all participate in the wider drug-safety ecosystem.

Outsourcing can provide specialized resources and operational capacity, while in-house teams enable companies to maintain direct oversight of safety activities and internal procedures.

Country and Regional Growth Outlook

FMI projects the following country-level growth rates through 2036:

·         China: 8.9% CAGR, supported by expanding procurement activity and growing pharmaceutical sector requirements.

·         India: 7.9% CAGR, reflecting healthcare expansion and increasing demand for drug-safety capabilities.

·         Germany: 7.3% CAGR, supported by pharmaceutical regulatory requirements and established life sciences infrastructure.

·         Brazil: 6.0% CAGR, reflecting demand for pharmaceutical safety oversight and expanding healthcare requirements.

The report also covers North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and the Middle East and Africa.

Major Market Trends and Growth Drivers

1.       Expanding clinical trial activity: Growing clinical development programs increase the need for adverse-event collection, medical review, safety reporting, and consistent documentation.

2.       Continued post-marketing surveillance: Pharmaceutical companies must continue monitoring medicines after authorization, making safety assessment a lifecycle requirement rather than a one-time activity.

3.       Digitalization and automation: Safety databases, workflow automation, and analytical tools can help manage large volumes of safety information, support case processing, and facilitate signal detection. Human expertise remains important for clinical assessment and regulatory decisions.

4.       Regulatory compliance and outsourcing: Companies are evaluating specialist service providers and technology platforms to support reporting obligations, operational capacity, and safety-system oversight across multiple markets.

Competitive Landscape

The pharmacovigilance market includes clinical research organizations, specialist safety service providers, and technology companies supporting drug-safety workflows. Competitive differentiation depends on scientific expertise, service coverage, operational quality, technology capabilities, and the ability to support clients across clinical development and post-authorization monitoring.

Access Full Report: https://www.futuremarketinsights.com/reports/pharmacovigilance-market

Key companies profiled by FMI include:

·         IQVIA

·         Parexel International Corporation

·         Clario

·         Pharmaceutical Product Development (PPD)

·         IBM Corporation

·         ICON plc

·         ArisGlobal

·         Syneos Health

·         Accenture

·         Cognizant

·         Capgemini

·         ProPharma Group

·         Freyr

Providers offering dependable case processing, qualified medical review, effective follow-up, and well-integrated safety workflows may be positioned to address pharmaceutical companies' evolving operational needs.

Analyst Perspective

“The pharmacovigilance market is shifting from fragmented buying toward consolidated supplier relationships as clinical phase buyers weigh total cost of ownership over list price. Suppliers that lower qualification friction and keep clinical phase specifications interoperable across buyer sites should secure the most durable procurement relationships over the forecast period.”

— Anurag Sharma, Principal Consultant at Future Market Insights

Related Reports:

·         Microplate Washer Market - https://www.futuremarketinsights.com/reports/microplate-washer-market

·         Synoptophore Market - https://www.futuremarketinsights.com/reports/synoptophore-market

·         Microwave Ablation Devices Market - https://www.futuremarketinsights.com/reports/microwave-ablation-devices-market

About Future Market Insights (FMI)

Future Market Insights (FMI) is a global market intelligence and consulting firm providing comprehensive market research, competitive intelligence, and strategic business insights across industries. The firm delivers detailed forecasts, technology analysis, and data-driven recommendations that support informed decision-making for manufacturers, investors, distributors, and policymakers worldwide.

For Press & Corporate Inquiries

Rahul Singh
AVP – Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075

For Sales – sales@futuremarketinsights.com
For Media – Rahul.singh@futuremarketinsights.com
For Web – https://www.futuremarketinsights.com